Palvella Therapeutics
PVLA
82 hedge funds and large institutions have $83.6M invested in Palvella Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 21 reducing their positions, and 16 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 21
22% more capital invested
Capital invested by funds: $68.8M → $83.6M (+$14.9M)
0.05% less ownership
Funds ownership: 0.79% → 0.75% (-0.05%)
7% less funds holding
Funds holding: 88 → 82 (-6)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $56K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.84M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.43M |
| 3 |
JP Morgan Chase
New York
|
+$449K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$397K |
| 5 |
BlackRock
New York
|
+$176K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$990K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$609K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$479K |
| 4 |
Cerity Partners
New York
|
-$468K |
| 5 |
Renaissance Technologies
New York
|
-$311K |
PVLA Hedge Fund Activity: Q4 2020 in Review
82 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2020, worth a combined $83.6M — up 22% from $68.8M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PVLA and 10 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 27 added.
The largest buyer was Morgan Stanley, adding an estimated $1.84M. The largest seller was Woodline Partners, cutting an estimated $990K.
- 82 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2020, down from 88 in Q3 2020.
- Funds reported $83.6M of Palvella Therapeutics stock for Q4 2020, up 22% quarter-over-quarter.
- 10 funds opened new Palvella Therapeutics positions in Q4 2020 and 16 closed out, a net change of -6 holders.
- The largest Palvella Therapeutics buyer in Q4 2020 was Morgan Stanley, an estimated $1.84M added.
- The largest Palvella Therapeutics seller in Q4 2020 was Woodline Partners, an estimated $990K sold.
Based on aggregated 13F filings for Q4 2020.